Research Journal of Oncology Open Access

  • Journal h-index: 4
  • Journal CiteScore: 0.30
  • Journal Impact Factor: 0.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Articles published in Research Journal of Oncology have been cited by esteemed scholars and scientists all around the world. Research Journal of Oncology has got h-index 4, which means every article in Research Journal of Oncology has got 4 average citations.

Following are the list of articles that have cited the articles published in Research Journal of Oncology.

  2022 2021 2020 2019 2018

Year wise published articles

30 11 35 16 16

Year wise citations received

30 11 36 8 16
Journal total citations count 33
Journal impact factor 0.24
Journal 5 years impact factor 0.30
Journal cite score 0.30
Journal h-index 4
Journal Impact Factor 2020 formula
IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year
Journal 5-year Impact Factor 2020 formula
Citations(2016 + 2017 + 2018 + 2019 + 2020)/
{Published articles(2016 + 2017 + 2018 + 2019 + 2020)}
Journal citescore
Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3
Important citations
Reducing chemotherapy administration time on an inpatient oncology unit
Epithelial-to-mesenchymal transition as the driver of changing carcinoma and glioblastoma microenvironment.
Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies.
Imaging After Treatment of Prostate Cancer
Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study.
Brachytherapy Combined With or Without Hormone Therapy for Localized Prostate Cancer: A Meta-Analysis and Systematic Review.
What pelvic radiation disease symptoms are experienced by patients receiving external beam radiotherapy and a high-dose-rate brachytherapy boost for prostate cancer?
miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT.
Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ?75 years with localized prostate cancer
Comparison of standard and delayed imaging to improve the detection rate of [ 68 Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer
Catheter-Directed Computed Tomography Hepatic Angiography for Yttrium-90 Selective Internal Radiotherapy of Hepatocellular Carcinoma Reduces Prophylactic Embolization of Extrahepatic Vessels
Retrospective Review of Tumor Response to Glass and Resin Y-90 Microsphere Treatments in Patients with Hepatocellular Carcinoma
Metformin ameliorated methotrexate-induced hepatorenal toxicity in rats in addition to its antitumor activity: two birds with one stone
Women who suffer from schizophrenia: Critical issues.
SIX FRACTAL CODES OF LIFE FROM BIOATOMS ATOMIC MASS TO CHROMOSOMES NUMERICAL STANDING WAVES: THREE BREAKTHOUGHS IN ASTROBIOLOGY, CANCERS AND ARTIFICIAL INTELLIGENCE
WUHAN COVID-19 SYNTHETIC ORIGINS AND EVOLUTION
Constitutional oncogenetics
Constitutional Oncogenetics